Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H19N3O4S |
| Molecular Weight | 397.448 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N2C
InChI
InChIKey=XMSXOLDPMGMWTH-UHFFFAOYSA-N
InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98241
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB129557
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
RIVOGLITAZONE
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
C521549
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
185428-18-6
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
C72841
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
DB09200
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
MM-22
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
8081
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
3A3N0634Q6
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
3055168
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104753
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
DTXSID00870164
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY | |||
|
100000155471
Created by
admin on Fri Dec 15 16:12:25 GMT 2023 , Edited by admin on Fri Dec 15 16:12:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
